Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FAB117-HC is an allogeneic cell therapy candidate developed by Ferrer for the treatment of acute traumatic spinal cord injury (SCI). The active ingredient, HC016, consists of adult mesenchymal stem cells (MSCs) derived from human adipose tissue. These cells undergo a specialized expansion process and are pulsed with hydrogen peroxide (H2O2) prior to administration. This pre-conditioning step is intended to enhance the cells' resilience and therapeutic potency, potentially improving their neuroprotective and regenerative effects within the inflammatory environment of an acute spinal injury. FAB117-HC is administered via a single intramedullary injection into the spinal cord lesion to promote functional recovery and mitigate secondary damage following trauma.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on FAB117-HC.